GeneDx Holdings Corp.
WGS
$166.95
$1.340.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.44% | 50.26% | 52.07% | 54.43% | 31.73% |
| Total Other Revenue | 119.32% | -13.79% | -52.01% | -52.36% | -39.62% |
| Total Revenue | 50.50% | 48.70% | 48.81% | 50.79% | 29.41% |
| Cost of Revenue | 12.80% | 9.90% | 3.71% | -2.15% | -34.14% |
| Gross Profit | 76.17% | 79.69% | 93.63% | 118.16% | 277.05% |
| SG&A Expenses | 26.48% | 12.67% | 3.82% | -11.46% | -26.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 14.26% | -68.18% | -75.35% | -84.08% | -88.25% |
| Total Operating Expenses | 23.13% | 10.84% | 0.84% | -10.42% | -31.87% |
| Operating Income | 123.35% | 109.30% | 89.48% | 86.78% | 80.72% |
| Income Before Tax | 102.98% | 101.30% | 71.75% | 70.21% | 81.66% |
| Income Tax Expenses | 158.08% | 115.20% | 121.60% | 62.96% | -71.76% |
| Earnings from Continuing Operations | 102.49% | 101.20% | 71.43% | 70.25% | 81.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.49% | 101.20% | 71.43% | 70.25% | 81.80% |
| EBIT | 123.35% | 109.30% | 89.48% | 86.78% | 80.72% |
| EBITDA | 246.57% | 161.96% | 110.85% | 99.67% | 88.62% |
| EPS Basic | 102.42% | 100.78% | 72.58% | 73.59% | 90.34% |
| Normalized Basic EPS | 125.58% | 115.46% | 80.66% | 79.08% | 81.71% |
| EPS Diluted | 101.84% | 100.37% | 72.51% | 73.54% | 90.33% |
| Normalized Diluted EPS | 125.03% | 115.05% | 80.66% | 79.08% | 81.71% |
| Average Basic Shares Outstanding | 7.21% | 6.92% | 6.26% | 10.67% | 27.35% |
| Average Diluted Shares Outstanding | 8.32% | 8.04% | 6.26% | 10.67% | 27.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |